Lernidum (Lercanidipine Hydrochloride)

Lernidum (Lercanidipine Hydrochloride) belongs to the calcium channel blocker class and is used to manage high blood pressure.

• Hypertension: lowers elevated blood pressure and reduces cardiovascular risk in adults.

• Lercanidipine Hydrochloride selectively inhibits L‑type calcium channels in vascular smooth muscle, preventing calcium influx. This causes relaxation of arterial smooth muscle, leading to vasodilation, reduced peripheral vascular resistance, and consequently a decrease in systemic blood pressure.

Lernidum may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often occurring after the first dose.
• Flushing: transient warmth and redness of the face or neck.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing.
• Severe hypotension: marked drop in blood pressure causing fainting or shock.
• Hepatic dysfunction: abnormal liver enzyme elevations indicating possible liver injury.

Before initiating therapy, clinicians should consider several safety factors.

• Monitor blood pressure: regular measurements to assess therapeutic response.
• Avoid abrupt discontinuation: taper the dose to prevent rebound hypertension.
• Caution in hepatic impairment: dose adjustment may be required.
• Use with caution in elderly patients: increased sensitivity to hypotensive effects.
• Review concomitant medications: assess for potential drug interactions.
• Store at room temperature: keep in the original container, protect from moisture and light.

Lernidum can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• Co‑administration with other antihypertensives that cause additive hypotension.
• Grapefruit juice: can raise drug exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Non‑dihydropyridine calcium channel blockers: may affect cardiac conduction.
• Diuretics: may enhance the antihypertensive response and increase risk of electrolyte imbalance.